JupiteX Get the app
Health & Medicine19 Nov 2026 · about 7 min

Health Ministry proposes to include antimicrobials in ‘New Drug’ definition, separate licence for bulk drug wholesale

The brief

The Ministry has proposed two changes to strengthen oversight at different points in the drug supply chain. One would bring antimicrobials into the “New Drug” definition under the New Drugs and Clinical Trials Rules, 2019. The other would create a separate licensing framework for the wholesale sale of bulk drugs. Both proposals respond to concerns about regulatory scrutiny and accountability. For antimicrobial manufacturing, companies would need permission from the Central Licensing Authority before applying to the relevant State Licensing Authority for a manufacturing licence. The Ministry cites studies such as bioavailability, bioequivalence and stability studies as examples of scrutiny that may be lacking. For wholesale, proposed Forms 19-BC and 20-BC would serve as the application and licence forms for bulk drugs. The changes are proposals, not stated as implemented. The DCC and DTAB agreed to them at meetings in November 2025 and February 2026. The proposed wholesale licence would record categories handled, including NDPS-covered drugs, and require a competent person’s personal supervision. The Ministry has invited objections and suggestions from the public and stakeholders.

01

What two changes is the Health Ministry proposing for antimicrobial manufacturing and bulk-drug wholesale?

The Ministry has proposed two changes to strengthen oversight at different points in the drug supply chain. One would bring antimicrobials into the “New Drug” definition under the New Drugs and Clinical Trials Rules, 2019. The other would create a separate licensing framework for the wholesale sale of bulk drugs. Both proposals respond to concerns about regulatory scrutiny and accountability.

For antimicrobial manufacturing, companies would need permission from the Central Licensing Authority before applying to the relevant State Licensing Authority for a manufacturing licence. The Ministry cites studies such as bioavailability, bioequivalence and stability studies as examples of scrutiny that may be lacking. For wholesale, proposed Forms 19-BC and 20-BC would serve as the application and licence forms for bulk drugs.

The changes are proposals, not stated as implemented. The DCC and DTAB agreed to them at meetings in November 2025 and February 2026. The proposed wholesale licence would record categories handled, including NDPS-covered drugs, and require a competent person’s personal supervision. The Ministry has invited objections and suggestions from the public and stakeholders.

02

What is a bulk drug, and how is it different from a finished medicine such as a tablet or injection?

In this proposal, “bulk drugs” means bulk substances—described in the article as active or inactive—that are sold wholesale. The article does not give a more detailed technical definition. In common pharmaceutical usage, an active pharmaceutical ingredient is the substance that produces a medicine’s intended effect; other ingredients can help make or deliver the dose.

A tablet or injection is a finished formulation: ingredients have been combined or prepared into a form and strength for use. For example, a medicine’s active ingredient may be made in bulk, then combined with other ingredients and shaped into tablets. An injectable medicine is prepared as a finished product for administration by injection. This illustrates the general distinction; it is not a specific example from the article.

The regulatory distinction matters because India currently uses a common wholesale licence for formulations and bulk drugs, according to the article. The proposed Drugs Rules amendment would create separate application Form 19-BC and licence Form 20-BC for bulk-drug sales. This would focus oversight on those substances and the wholesalers handling them. The article’s wording includes both active and inactive bulk substances.

03

What would a separate wholesale licence require, and how could it improve tracking of bulk drugs, including controlled substances?

The proposed framework would separate bulk-drug wholesale from the existing licensing provisions for formulations. Wholesalers would apply using Form 19-BC and, if licensed, receive Form 20-BC. The licence would capture the categories of bulk drugs handled. The proposal specifically includes drugs covered by the Narcotic Drugs and Psychotropic Substances Act, 1985.

For example, a wholesaler dealing in a category of bulk drug covered by the NDPS Act would have that category recorded under the proposed licence. Sales would take place under the personal supervision of a competent person. The article does not describe shipment-level records or a digital tracking system, so the tracking benefit is better understood as clearer licensing information and oversight of who handles which categories.

At present, one common licence covers wholesale sale of both formulations and bulk drugs. The Ministry says a dedicated framework could bring more focused oversight and accountability to the supply chain. It also says the proposal would strengthen enforcement control over the movement of NDPS drugs. The changes remain proposed; the Ministry has invited objections and suggestions from stakeholders and the public.

04

What are antimicrobials, and what kinds of microbes can these medicines act against?

Antimicrobials are medicines used to act against microorganisms, or microbes. The article does not define the term or list which organisms it covers. In established medical usage, the broad category includes antibacterial medicines such as antibiotics, as well as antiviral, antifungal and antiparasitic medicines. The exact medicine depends on the type of organism being targeted.

For example, an antibacterial medicine acts against bacteria, while an antiviral medicine targets viruses. These are different kinds of microbes, so one antimicrobial medicine should not be assumed to work against all of them. This distinction is general medical background, not an example or explanation supplied in the article. The article’s focus is on bringing antimicrobials within the rules for new drugs, rather than describing treatment choices.

The Ministry says antimicrobial resistance is a major global public health concern. Its proposed amendment would place antimicrobials under the regulatory framework for new drugs, including a requirement to seek Central Licensing Authority permission before applying for a State manufacturing licence. The aim stated in the article is stronger oversight to help ensure antimicrobial products’ quality, safety and efficacy. The proposal does not specify particular antimicrobial classes.

05

Why would regulators require central permission and studies of a drug’s absorption, equivalence, and stability before allowing it to be made?

The article links the proposed controls to concerns that antimicrobial manufacturing licences may be granted without adequate regulatory scrutiny. It names bioavailability, bioequivalence and stability studies as examples of studies that may be required. The Ministry’s stated aim is to bring antimicrobials under the regulatory framework that applies to new drugs and strengthen central oversight.

Bioavailability studies examine how much of a medicine reaches the body’s circulation and how quickly. Bioequivalence studies compare whether two products deliver the active ingredient in a sufficiently similar way. Stability studies assess whether a product maintains its quality over time under specified conditions. These descriptions are general scientific background; the article does not set out study protocols or say that every study applies to every product.

Under the proposal, a manufacturer would first obtain permission from the Central Licensing Authority, then apply to the concerned State Licensing Authority for a manufacturing licence. The article says this is expected to help ensure antimicrobial products’ quality, safety and efficacy. It reports the change as proposed, not yet implemented, and invites stakeholders and the public to submit objections and suggestions.

06

How does antimicrobial resistance develop, and why can poor-quality or improperly used medicines make it worse?

Antimicrobial resistance, or AMR, develops when microorganisms change over time so that medicines that once controlled them work less well or no longer work. Resistant microbes can survive treatment and multiply. This is established medical background; the article itself identifies AMR as a major global public health concern but does not explain its biological development.

Poor-quality medicines may contain too little active ingredient or fail to maintain their quality, while improper use can expose microbes to medicines in ways that favour resistant survivors. These are general explanations of how medicine quality and use can contribute to resistance, not specific findings reported in the article. The article’s concern is that antimicrobial products could receive manufacturing licences without adequate regulatory scrutiny, including studies such as stability checks.

The Ministry proposes classifying antimicrobials as new drugs under the 2019 Rules. Manufacturers would need Central Licensing Authority permission before applying for a State manufacturing licence. The stated purpose is stronger oversight and help ensuring quality, safety and efficacy. The proposal does not claim that any particular product caused resistance or describe controls on how patients use medicines.

07

How large is the global health burden of antimicrobial resistance?

The source article describes antimicrobial resistance as a major global public health concern, but it does not quantify its worldwide burden. For scale, a WHO-led analysis published in The Lancet estimated that bacterial antimicrobial resistance was directly responsible for 1.27 million deaths in 2019 and associated with 4.95 million deaths that year. These figures are external context, not figures from the article.

The two estimates describe different measures. “Attributable” deaths are those estimated to have occurred because of resistance, compared with a scenario in which drug-susceptible infections were present. “Associated” deaths include a broader group of deaths linked to resistant infections, whether or not resistance itself was the direct cause. The estimates cover bacterial AMR, not every form of antimicrobial resistance.

The article gives no burden estimate, but it connects the global concern to proposed regulatory changes in India. These would bring antimicrobials under new-drug rules and introduce central permission before manufacturers seek State licences. The stated goal is stronger scrutiny of product quality, safety and efficacy. The article does not say what effect the proposed changes would have on global AMR figures.

This brief was written by AI from the original reporting and checked by other models. Names, figures and quotes come from the source; read it for full context.

Read more in the JupiteX app

Pulse is free. New stories every 4 hours, each one broken into the questions that explain it.

Or read more news on the web